Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less ... more

• Genetics and Evolution of Infectious Diseases

  EURO€ 115.00USD$ 150.00GBP£ 97.00AUD$ 146.00JPY¥ 14,772.00SEK 982,00CHF 141.00CAD$ 152.00 Elsevier Science and Technology, Dec 2010 , Pages: 772
  This multidisciplinary book is at the crossroads between two major scientific fields of the 21st century: evolutionary biology and infectious diseases. The genomic revolution has upset modern biology...

• Handbook of Acute Pain Management

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Informa Healthcare, Dec 2010 , Pages: 300
  Pain is a pervasive symptom present in multiple areas of medicine. It is imperative that physicians not only evaluate and diagnose the source of pain, but that they also recognize how to manage the...

• Handbook of Acute Pain Management

  EURO€ 291.00USD$ 378.00GBP£ 244.00AUD$ 370.00JPY¥ 37,321.00SEK 2 482,00CHF 356.00CAD$ 385.00 Informa Healthcare, Dec 2010 , Pages: 300
  Pain is a pervasive symptom present in multiple areas of medicine. It is imperative that physicians not only evaluate and diagnose the source of pain, but that they also recognize how to manage the...

• Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 221
  The epilepsy market has become increasingly competitive following the launch of Vimpat (lacosamide; UCB) in the US in May 2009 and patent expiries of the top four second-generation anticonvulsant drugs...

• Cardiovascular Pharmacology: Endothelial Control, Vol 60

  EURO€ 183.00USD$ 238.00GBP£ 154.00AUD$ 233.00JPY¥ 23,506.00SEK 1 563,00CHF 224.00CAD$ 243.00 Elsevier Science and Technology, Dec 2010 , Pages: 336
  Cardiovascular disease remains a major cause of death and disability in developed countries and, increasingly so, in the developing world. Presented in this volume of Advances in Pharmacology are some...

• China Chinese Patent Medicine Industry Report, 2010

  EURO€ 1,076.00USD$ 1,400.00GBP£ 905.00AUD$ 1,369.00JPY¥ 138,226.00SEK 9 192,00CHF 1'320.00CAD$ 1,427.00 Research In China, Dec 2010 , Pages: 53
  China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world Driven by both policy incentives and market demand, Chinese patent medicine...

• China Chinese Patent Medicine Industry Report, 2010

  EURO€ 1,076.00USD$ 1,400.00GBP£ 905.00AUD$ 1,369.00JPY¥ 138,226.00SEK 9 192,00CHF 1'320.00CAD$ 1,427.00 Research In China, Dec 2010 , Pages: 53
  China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world Driven by both policy incentives and market demand, Chinese patent medicine...

• Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases

  EURO€ 900.00USD$ 1,171.00GBP£ 757.00AUD$ 1,145.00JPY¥ 115,604.00SEK 7 688,00CHF 1'104.00CAD$ 1,193.00 La Merie Publishing, Dec 2010 , Pages: 172
  The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed...

• Russian Inulin And Oligofructose Market 2010

  EURO€ 1,550.00USD$ 2,017.00GBP£ 1,304.00AUD$ 1,972.00JPY¥ 199,095.00SEK 13 240,00CHF 1'901.00CAD$ 2,055.00 Centripap, Dec 2010 , Pages: 35
  One in a series of reports focusing on prebiotic ingredients, this comprehensive analysis of the Russian market for prebiotic-fructans examines estimated ingredient consumption, key trends by application,...

• OTC Market in Poland 2010: Switch Strategies and Development Forecasts for 2010-2012

  EURO€ 1,800.00USD$ 2,342.00GBP£ 1,514.00AUD$ 2,290.00JPY¥ 231,208.00SEK 15 376,00CHF 2'207.00CAD$ 2,386.00 PMR Ltd, Dec 2010 , Pages: 209
  The report is a comprehensive analysis of the OTC market in Poland, with a closer look at drugs, dietary supplements and dermocosmetics The historical data and development forecasts for the individual...

• OTC Market in Poland 2010: Switch Strategies and Development Forecasts for 2010-2012

  EURO€ 1,800.00USD$ 2,342.00GBP£ 1,514.00AUD$ 2,290.00JPY¥ 231,208.00SEK 15 376,00CHF 2'207.00CAD$ 2,386.00 PMR Ltd, Dec 2010 , Pages: 209
  The report is a comprehensive analysis of the OTC market in Poland, with a closer look at drugs, dietary supplements and dermocosmetics The historical data and development forecasts for the individual...

• 2011 Worldwide Pharmaceutical Preparation Mfg. Industry Report

  EURO€ 191.00USD$ 249.00GBP£ 161.00AUD$ 244.00JPY¥ 24,585.00SEK 1 635,00CHF 235.00CAD$ 254.00 Barnes Reports, Dec 2010 , Pages: 104
  The Pharmaceutical Preparation Mfg. Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 forecast...

• 2011 Worldwide Community Care Facilities for the Elderly Industry Report

  EURO€ 191.00USD$ 249.00GBP£ 161.00AUD$ 244.00JPY¥ 24,585.00SEK 1 635,00CHF 235.00CAD$ 254.00 Barnes Reports, Dec 2010 , Pages: 104
  The Community Care Facilities for the Elderly Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and...

• 2011 Worldwide Pharmacies & Drug Stores Industry Report

  EURO€ 191.00USD$ 249.00GBP£ 161.00AUD$ 244.00JPY¥ 24,585.00SEK 1 635,00CHF 235.00CAD$ 254.00 Barnes Reports, Dec 2010 , Pages: 104
  The Pharmacies & Drug Stores Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 forecast estimates...

• 2011 Worldwide Offices of Physicians Industry Report

  EURO€ 191.00USD$ 249.00GBP£ 161.00AUD$ 244.00JPY¥ 24,585.00SEK 1 635,00CHF 235.00CAD$ 254.00 Barnes Reports, Dec 2010 , Pages: 104
  The Offices of Physicians Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2011 current and 2012 forecast estimates...

• Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 267
  The German prescription pharmaceutical market was valued at $38.3 bn in 2009, with an annual growth rate of 4.4% between 2008 and 2009. However, future market growth will be hampered by the newly introduced...

• Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 285
  Introduction The urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new products driven by large marketing campaigns. Promotional efforts will remain...

• Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus - Increasing attention for neglected diseases

  EURO€ 2,921.00USD$ 3,800.00GBP£ 2,457.00AUD$ 3,717.00JPY¥ 375,185.00SEK 24 950,00CHF 3'582.00CAD$ 3,872.00 Datamonitor, Dec 2010 , Pages: 204
  Dengue, Japanese encephalitis and West Nile virus are major causes of disease worldwide. Dual market pricing strategies for endemic countries and the Western travelers market offer great commercial...

• Innovative Drug Discovery in Emerging Markets

  EURO€ 2,948.00USD$ 3,835.00GBP£ 2,480.00AUD$ 3,751.00JPY¥ 378,641.00SEK 25 180,00CHF 3'615.00CAD$ 3,908.00 Scripp Business Insights, Dec 2010 , Pages: 215
  Emerging markets have represented important growth opportunities for the global pharmaceutical industry, but it has been unclear the extent to which this has been accompanied by growth in domestic innovation...

• Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010
  The "Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers" report is due to be published in December 2010 This report will cover the following key topics: - Pipeline Overview and Dynamics...

• U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016)

  EURO€ 3,574.00USD$ 4,650.00GBP£ 3,007.00AUD$ 4,548.00JPY¥ 459,108.00SEK 30 531,00CHF 4'383.00CAD$ 4,738.00 Markets and Markets, Dec 2010 , Pages: 378
  The U S biopharmaceuticals market is expected to increase to $144 billion by 2016 The growth is expected as a result of the launch of new products, approval of new indications for existing therapies...

• Generic Drug Market in Japan 2010

  EURO€ 2,336.00USD$ 3,038.00GBP£ 1,965.00AUD$ 2,972.00JPY¥ 300,000.00SEK 19 950,00CHF 2'864.00CAD$ 3,096.00 Yano Research Institute Ltd, Dec 2010 , Pages: 187
  Generic Drug Market in Japan 2010 is a comprehensive resource book on the current generic drug market in Japan It provides you with a full picture of the market by covering market size, market share,...

• Generic Drug Market in Japan 2010

  EURO€ 2,336.00USD$ 3,038.00GBP£ 1,965.00AUD$ 2,972.00JPY¥ 300,000.00SEK 19 950,00CHF 2'864.00CAD$ 3,096.00 Yano Research Institute Ltd, Dec 2010 , Pages: 187
  Generic Drug Market in Japan 2010 is a comprehensive resource book on the current generic drug market in Japan It provides you with a full picture of the market by covering market size, market share,...

• Allergic Rhinitis Market Forecast

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010
  2009 allergic rhinitis sales are estimated at $5 billion in the seven major markets, and a decline to $4 billion is forecast by 2019 The greatest threat to the market is generics, with drug classes...

• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 416
  Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy The non-insulins antidiabetics market is forecast to grow to $18 8 billion...

• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 416
  Introduction Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists...

• Australia Pharmaceuticals and Healthcare Report Q1 2011

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Dec 2010 , Pages: 90
  Australia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent...

• Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 167
  Introduction Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable...

• Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 268
  Introduction There are currently 100 drugs in the pipeline for melanoma, thyroid cancer and neuroendocrine tumors with 16 in late-stage. After years of little progress there are drugs in pre-registration...

• Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 124
  Introduction Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in 2009 to $11.2bn in 2019 across the seven major markets. In this cost-competitive...

• United Therapeutics Oral Treprostinil (UT-15C SR) - Likelihood of clinical trial and commercial success

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 LifeTech Research, Dec 2010 , Pages: 34
  UT-15C SR might be United Therapeutics’ fourth treprostinil formulation to reach the market, but as an oral agent it could be the most convenient of them all However, UT-15C SR’s road to market has...

• Fibromyalgia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 38
  Fibromyalgia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Fibromyalgia Pipeline Review, Q4 2010”, provides an overview of the Fibromyalgia therapeutic pipeline. This report provides...

• China Pharmaceutical Chain Industry Report, 2010

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 Research In China, Dec 2010 , Pages: 55
  Recent years have seen rapid growth of China’s pharmaceutical retail market, with expanding scale of chain enterprises and increasing number of drugstores, thanks to a fast-growing pharmaceutical industry...

• China Pharmaceutical Chain Industry Report, 2010

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 Research In China, Dec 2010 , Pages: 55
  Recent years have seen rapid growth of China’s pharmaceutical retail market, with expanding scale of chain enterprises and increasing number of drugstores, thanks to a fast-growing pharmaceutical industry...

• Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 182
  Introduction While general COPD treatment patterns are consistent across the emerging markets compared to the US, some key distinctions between countries have been identified, which impact market potential...

• Macular Edema - Drug Pipeline Analysis and Market Forecasts to 2016

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Dec 2010 , Pages: 39
  “Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global macular edema therapeutics market The report identifies...

• Cystic Fibrosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 81
  Cystic Fibrosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Cystic Fibrosis Pipeline Review, Q4 2010”, provides an overview of the Cystic Fibrosis therapeutic pipeline. This report...

• Dengue - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 41
  Dengue - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dengue Pipeline Review, Q4 2010”, provides an overview of the Dengue therapeutic pipeline. This report provides information on the...

• Migraine - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 83
  Migraine - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Migraine Pipeline Review, Q4 2010”, provides an overview of the Migraine therapeutic pipeline. This report provides information...

• Colorectal Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 582
  Colorectal Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Colorectal Cancer Pipeline Review, Q4 2010”, provides an overview of the Colorectal Cancer therapeutic pipeline. This...

• Influenza - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 130
  Influenza - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Influenza Pipeline Review, Q4 2010”, provides an overview of the Influenza therapeutic pipeline. This report provides information...

• Anemia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 129
  Anemia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Anemia Pipeline Review, Q4 2010”, provides an overview of the Anemia therapeutic pipeline. This report provides information on the...

• Atrial Fibrillation - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 75
  Atrial Fibrillation - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Atrial Fibrillation Pipeline Review, Q4 2010”, provides an overview of the Atrial Fibrillation therapeutic pipeline....

• HIV-1 Infection - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 76
  HIV-1 Infection - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “HIV-1 Infection Pipeline Review, Q4 2010”, provides an overview of the HIV-1 Infection therapeutic pipeline. This report...

• Nonalcoholic Steatohepatitis (NASH) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Nonalcoholic Steatohepatitis (NASH) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Nonalcoholic Steatohepatitis (NASH) Pipeline Review, Q4 2010”, provides an overview of the Nonalcoholic...

• Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 216
  Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Non-Hodgkin Lymphoma Pipeline Review, Q4 2010”, provides an overview of the Non-Hodgkin Lymphoma therapeutic pipeline....

• Asthma - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 186
  Asthma - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Asthma Pipeline Review, Q4 2010”, provides an overview of the Asthma therapeutic pipeline. This report provides information on the...

• HIV / AIDS - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 383
  HIV / AIDS - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “HIV and Aids Pipeline Review, Q4 2010”, provides an overview of the HIV and Aids therapeutic pipeline. This report provides...

• Gastric Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 196
  Gastric Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Gastric Cancer Pipeline Review, Q4 2010”, provides an overview of the Gastric Cancer therapeutic pipeline. This report provides...

• Polycystic Ovarian Syndrome - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 37
  Polycystic Ovarian Syndrome - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Polycystic Ovarian Syndrome Pipeline Review, Q4 2010”, provides an overview of the Polycystic Ovarian Syndrome...